Cartesian Therapeutics (RNAC) Leases: 2018-2025
Historic Leases for Cartesian Therapeutics (RNAC) over the last 6 years, with Sep 2025 value amounting to $5.0 million.
- Cartesian Therapeutics' Leases fell 63.23% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year decrease of 63.23%. This contributed to the annual value of $5.5 million for FY2024, which is 45.02% down from last year.
- Cartesian Therapeutics' Leases amounted to $5.0 million in Q3 2025, which was down 3.72% from $5.2 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Leases registered a high of $13.9 million during Q2 2024, and its lowest value of $3.2 million during Q4 2022.
- Moreover, its 3-year median value for Leases was $10.1 million (2023), whereas its average is $9.1 million.
- Its Leases has fluctuated over the past 5 years, first tumbled by 67.44% in 2022, then spiked by 214.63% in 2023.
- Over the past 5 years, Cartesian Therapeutics' Leases (Quarterly) stood at $9.8 million in 2021, then crashed by 67.44% to $3.2 million in 2022, then surged by 214.63% to $10.1 million in 2023, then tumbled by 45.02% to $5.5 million in 2024, then tumbled by 63.23% to $5.0 million in 2025.
- Its Leases was $5.0 million in Q3 2025, compared to $5.2 million in Q2 2025 and $5.4 million in Q1 2025.